Alcon (ALC) Stock
Key stats
- Market cap
- $37.00B
- Price / Earnings ratio
- 58.1x
- EPS (TTM)
- $1.31
- Volume
- Loading
- 52-week high
- $87.64
- 52-week low
- $61.84
- Dividend yield
- 0.77%
- Dividend amount (latest)
- $0.59
- EPS vs analyst estimate
- -3.7%Q3 FY25 · $0.79 vs $0.82
- Next earnings report
- 10 Nov 2026
Source: third-party data provider, as of November 7, 2026
EPS estimate: analyst consensus
Compare with ALC
Recent news

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
ALC

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
ALC

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
ALC

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
ALC
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 72.51
- MACD 12/26/9
- 2.35
- EMA 9 of MACD
- 1.40
- MACD histogram
- 0.95
- SMA 50
- $67.77
- Price above SMA 50
- EMA 50
- $68.81
- Price above EMA 50
- SMA 200
- $71.85
- Price above SMA 200
- EMA 200
- $71.97
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.84 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
ALC

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
ALC

FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
ALC

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
ALC

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
ALC

$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
ALC

Alcon Prices EUR 500 Million Senior Notes Offering
Alcon Prices EUR 500 Million Senior Notes Offering
ALC

Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
ALC

Eye care company Alcon raises profitability outlook, cuts tariff hit estimate
Eye care company Alcon raises profitability outlook, cuts tariff hit estimate
ALC

Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ALC
News tone: automated (AI) classification of the article's content, not a price prediction.
About Alcon
Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With our 70-plus-year heritage, we are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. David J. Endicott | CEO & Director | 1965 |
| Mr. Timothy C. Stonesifer | Senior VP & CFO | 1967 |
| Mr. Ian Bell | Senior VP & COO | 1971 |
| Margaret Buckley | Chief Accounting Officer | — |
| Dr. Franck Leveiller Ph.D. | SVP of Global Research & Development and Chief Scientific Officer | — |
| Mr. Muru Murugappan | Senior VP and Chief Information & Transformation Officer | — |
| Mr. Royce R. Bedward J.D. | Senior VP, General Counsel & Corporate Secretary | 1966 |
| Ms. Kimberly Martin | Senior VP and Chief HR & Corporate Communications | 1975 |
| Mr. Leon Sergio Duplan Fraustro | Senior VP & President of Americas | 1968 |
| Mr. Laurent Attias | Senior VP of Corporate Strategy, Business Development and Licensing (BD&L), M&A | 1968 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 72.51
- MACD 12/26/9
- 2.35
- EMA 9 of MACD
- 1.40
- MACD histogram
- 0.95
- SMA 50
- $67.77
- Price above SMA 50
- EMA 50
- $68.81
- Price above EMA 50
- SMA 200
- $71.85
- Price above SMA 200
- EMA 200
- $71.97
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $70.00
- Average
- $81.57
- High
- $98.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.1 | +11.2 | ||||||||||
| 2022 | -11.9 | -1.5 | +4.2 | -10.7 | +5.5 | -5.9 | +9.1 | -15.9 | -12.4 | +2.2 | +13.9 | -2.2 |
| 2023 | +9.0 | -10.7 | +3.8 | +4.4 | +7.5 | +4.4 | +4.8 | -0.8 | -6.6 | -5.4 | +4.6 | +3.0 |
| 2024 | -2.5 | +10.7 | -4.0 | -5.4 | +13.5 | -0.6 | +6.7 | +4.1 | +4.6 | -7.2 | -3.2 | -3.8 |
| 2025 | +9.2 | +2.3 | +0.8 | +5.3 | -10.6 | +3.7 | -1.7 | -9.2 | -4.8 | -1.6 | +7.3 | +0.8 |
| 2026 | +4.4 | +9.8 | -11.0 | -0.8 | -10.5 | +2.1 | +3.2 | +2.6 | -9.8 | +11.7 | +4.0 |
Corporate actions
Upcoming
No upcoming corporate actions for ALC



